… , low-volume tumors. Topical treatment including BCG and mitomycin and BCG with interferon-…
combined with 50–100 million units interferon-alpha2b can be instilled in the office setting …

… The most robust evidence exists for BCG, particularly in the setting of CIS of the upper tract.
… predict a patient’s response to BCG would help in stratifying a patient to surgical or topical …

… on adjuvant BCG therapy. … upper tract transitional cell carcinoma received biopsy and
ablation of papillary lesions, followed by a 6-week course of topical retrograde induction with BCG-…

… the utility of BCG in the adjuvant setting. … upper tract instillation of BCG and topical
chemotherapy showing some benefit to CIS but little clear role in Ta/T1 disease. With new therapies …

… BCG) after KSS for papillary noninvasive (Ta-T1) UTUCs and of adjuvant BCG for the treatment
… After KSS, topical agents can be administered with an antegrade approach through a …

… However genital skin rash was more common (08.14%) in … useful therapy and prophylaxis
for transitional cell carcinoma … exposure because in our set up females are restricted to home …

… The multivariate analysis revealed that topical BCG therapy … , patients treated in the primary
setting with BCG for UUT-CIS … drug in the adjuvant setting after ablation of Ta/T1 tumours. …

… However, energy settings must be reduced due … BCG, while the remaining 13 renal units
had recurrent or relapsing papillary tumors and received salvage therapy with mitomycin C, BCG…

… BCG regimens and 6 once monthly maintenance treatments for chemo regimens. Patients
were preferentially treated with a BCG regimen unless previously BCG … , upper tract imaging …

… a real risk of dialysis in the setting of bilateral tumours, tumour in … carcinoma of the skin,
squamous cell carcinoma of the skin, … in all cases of upper tract transitional cell carcinoma? Long-…